Performance of sulfhydryl boron hydride in patients with grade III and IV astrocytoma: a basis for boron neutron capture therapy.
This study investigated the rationale of boron neutron capture therapy (BNCT) for the treatment of Grade III and IV astrocytoma. The European Community joint research program on BNCT plans to use sulfhydryl boron hydride (BSH) in clinical trials. The work presented here, examines the performance of BSH in eight patients with Grade III and IV astrocytoma using a measurement technique which precisely correlates the boron uptake with the histology of the tumor and the peritumoral brain. Astrocytomas are exceptionally heterogeneous and spread migrating tumor cells into the surrounding brain. The patients were infused with 50 mg BSH per kilogram of body weight at 12, 18, 24 or 48 hours before surgery. At the time of operation, specimens were obtained of the tumor, skin, muscle, dura, blood, urine, and, when surgically possible, the brain adjacent to tumor. In three patients the intracellular boron distribution was investigated by subcellular fractionation. The blood clearance was biphasic with half-lives of 0.6 and 8.2 hours. After 3 days, approximately 70% of the dose injected was excreted in the urine. The maximum boron concentration in the tumor was 20 ppm, 12 hours after the infusion. The tumor-to-blood ratios ranged between 0.2 and 1.4, with the highest values after 18 to 24 hours. In the brain specimens the boron concentration never exceeded 1 ppm. This work confirms a selective uptake of boron in the tumor compared to the surrounding brain and that boron, to some extent, is incorporated in the tumor cells.
Ceberg
C P
CP
Department of Radiation Physics, Lund University Hospital, Sweden.
Persson
A
A
Brun
A
A
Huiskamp
R
R
Fyhr
A S
AS
Persson
B R
BR
Salford
L G
LG
D001254:Astrocytoma / Q000175:diagnosis / Q000378:metabolism / Q000532:radiotherapy*; D001706:Biopsy; D001825:Body Fluid Compartments; D001894:Borohydrides / Q000627:therapeutic use*; D001895:Boron / Q000493:pharmacokinetics; D016754:Boron Neutron Capture Therapy; D001921:Brain / Q000473:pathology / Q000528:radiation effects; D001932:Brain Neoplasms / Q000175:diagnosis / Q000378:metabolism / Q000532:radiotherapy*; D006207:Half-Life; D006801:Humans; D016018:Least-Squares Analysis; D013438:Sulfhydryl Compounds / Q000627:therapeutic use*; D014018:Tissue Distribution; D014057:Tomography, X-Ray Computed
D001894:Borohydrides; D013438:Sulfhydryl Compounds; C014651:mercaptoundecahydrododecaborate; D001895:Boron